Clinical Trial Update: A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 trial of a novel MUC1-expressing vaccine for tumor malignancies has been withdrawn, including multiple myeloma as an indicated condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Multiple Myeloma, Tumors | Phase 2 | Status: WITHDRAWN